FDA adds a warning to Covid-19 vaccines about risk of heart inflammation

▴ fda_adds_a_warning_to_covid-19_vaccines_medicircle
FDA say benefits outweigh the heart problem risks

The US Food and Drug Administration added a warning about the risk of myocarditis and pericarditis to fact sheets for Moderna and Pfizer-BioNTech Covid-19 vaccines Friday.

The warning notes that reports of adverse events following vaccination -- particularly after the second dose -- suggest increased risks of both types of heart inflammation.

Earlier this week, vaccine advisers to the US Centers for Disease Control and Prevention heard that the agency had received about 1,200 reports of such heart inflammation after 300 million doses of the two vaccines had been given. CDC has confirmed about 300 of those cases, many of them among young men and adolescents.

But patients are recovering quickly, Dr Matthew Oster, a pediatric cardiologist, told the advisers.

The FDA is advising vaccine recipients to seek immediate medical attention if they experience "chest pain, shortness of breath, or feelings of having a fast-beating, fluttering, or pounding heart after vaccination."

"This update follows an extensive review of information and the discussion by CDC's Advisory Committee on Immunization Practices meeting on Wednesday," the FDA said.

"The data presented at this meeting reinforced the FDA's decision to revise the fact sheets and further informed the specific revisions."

ACIP members agreed there is a likely association between the mRNA Covid-19 vaccines and rare cases of heart inflammation in adolescents and young adults. Almost all the cases resolved with little treatment and patients recovered quickly. The advisers said that the benefits of vaccination outweigh the risks.


The FDA said at the time it would update the fact sheets the reflect the findings.
"The data presented at this meeting reinforced the FDA's decision to revise the fact sheets and further informed the specific revisions," the FDA said in a statement.


Both the FDA and CDC are monitoring reports of these adverse events and will follow up to assess longer-term outcomes, the FDA noted.

Tags : #FDA #CDC #CovidVaccines #MrnaVaccine #HeartInflammation

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026